Advances in Antimicrobial Peptides

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: 15 March 2025 | Viewed by 1107

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Biochemistry and Molecular Biology, Federal University of Ceará, Fortaleza 60020-181, Brazil
2. Drug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza 60430-160, Brazil
Interests: anti-bacterial agents; polypeptide antibiotic agent; antimicrobial cationic peptides

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the growing significance of antimicrobial peptides (AMPs) as promising agents in the fight against infectious diseases and antimicrobial resistance. AMPs, naturally occurring molecules found across various organisms, exhibit a broad spectrum of activity against bacteria, viruses, fungi, and even cancer cells. As traditional antibiotics face diminishing efficacy due to rising resistance, AMPs offer a novel alternative for therapeutic interventions.

This Special Issue seeks to highlight cutting-edge research and advancements in the field of antimicrobial peptides. We invite original research articles, reviews, and perspectives that explore the following topics, including, but not limited to, the following:

  • Mechanisms of action: Investigations into the molecular mechanisms underlying the antimicrobial activities of AMPs and their interactions with microbial membranes and intracellular targets.
  • Novel AMPs discovery: Identification and characterization of new antimicrobial peptides from natural sources, including plants, animals, and microorganisms.
  • Design and engineering of AMPs: Studies focusing on the design, optimization, and synthetic production of AMPs to enhance their stability, specificity, and antimicrobial potency.
  • Therapeutic applications: Exploration of AMPs as therapeutic agents for treating infections, including their potential roles in combating drug-resistant pathogens and biofilm-associated infections.
  • AMPs in immunomodulation: Research on the immunomodulatory properties of AMPs and their ability to regulate immune responses in host defense mechanisms.
  • Clinical trials and applications: Updates on clinical trials involving AMPs and their application in medicine, agriculture, and food safety.
  • AMPs and nanotechnology: Integration of AMPs with nanotechnology for the development of novel antimicrobial materials and drug delivery systems.

Dr. Pedro F.N. Souza
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial peptides (AMPs)
  • drug-resistant pathogens
  • membrane disruption
  • immunomodulation
  • biofilm inhibition
  • peptide design and engineering
  • therapeutic applications
  • synthetic peptides
  • host defense peptides
  • nanotechnology-based AMPs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 8712 KiB  
Article
A Tachyplesin Antimicrobial Peptide from Theraphosidae Spiders with Potent Antifungal Activity Against Cryptococcus neoformans
by Brenda B. Michira, Yi Wang, James Mwangi, Kexin Wang, Demeke Asmamaw, Dawit Adisu Tadese, Jinai Gao, Mehwish Khalid, Qiu-Min Lu, Ren Lai and Juan Li
Microorganisms 2024, 12(12), 2648; https://doi.org/10.3390/microorganisms12122648 - 20 Dec 2024
Viewed by 842
Abstract
The venoms of Theraphosidae spiders have evolved into diverse natural pharmacopeias through selective pressures. Cryptococcus neoformans is a global health threat that frequently causes life-threatening meningitis and fungemia, particularly in immunocompromised patients. In this study, we identify a novel anti-C. neoformans peptide, [...] Read more.
The venoms of Theraphosidae spiders have evolved into diverse natural pharmacopeias through selective pressures. Cryptococcus neoformans is a global health threat that frequently causes life-threatening meningitis and fungemia, particularly in immunocompromised patients. In this study, we identify a novel anti-C. neoformans peptide, QS18 (QCFKVCFRKRCFTKCSRS), from the venom gland of China’s native spider species Chilobrachys liboensis by utilizing bioinformatic tools. QS18 shares over 50% sequence similarity with tachyplesin peptides, previously identified only in horseshoe crab hemocytes, expanding the known repertoire of the tachyplesin family to terrestrial arachnids. The oxidative folding of QS18 notably enhances its antifungal activity and stability, resulting in a minimum inhibitory concentration of 1.4 µM. The antimicrobial mechanism of QS18 involves cell membrane disruption. QS18 exhibits less than 5% hemolysis in human erythrocytes, indicating microbial selectivity and a favorable safety profile for therapeutic use. Furthermore, mouse model studies highlight QS18’s ability as an antifungal agent with notable anti-inflammatory activity. Our study demonstrates QS18 as both a promising template for spider venom peptide research and a novel candidate for the development of peptide antifungals. Full article
(This article belongs to the Special Issue Advances in Antimicrobial Peptides)
Show Figures

Figure 1

Back to TopTop